CEPI – Coalition for Epidemic Preparedness Innovations  [to 14 October 2017]
CEPI vaccine R&D pipeline and cost tracking survey
CEPI is inviting you to participate in a survey that is mapping vaccine research and development pipelines and associated costs for emerging infectious diseases.
The survey is open until 10 November 2017.
To achieve its strategic objectives, and to make efficient use of its financial resources, CEPI needs to draw on a variety of vaccine candidates and leverage diversity of product development partners. CEPI is currently building up a comprehensive knowledge base on available vaccine candidates and their current status, in order to serve vaccine preparedness needs against non-commercial epidemic disease threats…

EDCTP    [to 14 October 2017]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
9 October 2017
EDCTP joins forces with WHO AFRO and TDR to fund implementation research
A new partnership has been formed between EDCTP, TDR (the Special Programme for Research and Training in Tropical Diseases), and the World Health Organization’s Regional Office for Africa (WHO AFRO) in recognition of a mutual interest in strengthening the capacity for health research in African countries. Collaboration between these three partners has been realised through a recently launched call “Joint WHO-AFRO/TDR/EDCTP Small Grants Scheme for implementation research on infectious diseases of poverty”, which will close on 30 November 2017…

European Medicines Agency  [to 14 October 2017]
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2017
One generic medicine recommended for approval …
FDA [to 14 October 2017]
October 11, 2017 –
Statement by FDA Commissioner Scott Gottlieb, M.D. on new steps by FDA to advance patient engagement in the agency’s regulatory work
The Food and Drug Administration is hosting a pioneering event today: the first meeting of the Patient Engagement Advisory Committee or PEAC. It’s a significant step forward in the FDA’s efforts to broaden its engagement with patients – and to deepen the involvement of patients in our regulatory activities.
This is the agency’s first advisory committee that’s comprised solely of patients, care-partners, and those who represent their needs. Founded by the FDA’s Center for Devices and Radiological Health (CDRH), it reflects CDRH’s commitment to keep patients at the center of their work.
The FDA’s work requires us to establish objective, consistent criteria on which we base our decisions. But ultimately, the criteria we use to judge benefit and risk turn on the parameters that matter to patients.
Involving the end-user – the patient – in identifying health priorities and outcomes desired from health interventions is critically important…
Global Fund [to 14 October 2017];&country=
Global Fund and The Union Deepen Partnership to Fight TB
11 October 2017
The Global Fund to Fight AIDS, Tuberculosis and Malaria and the International Union against Tuberculosis and Lung Disease, also known as The Union, announced a partnership agreement to deepen their shared commitment to end tuberculosis as an epidemic.
Partners Launch Global Effort to Find Missing Cases of TB
09 October 2017
Global health partners and implementers from 13 countries with a high burden of tuberculosis launched an ambitious program to find and treat an additional 1.5 million missing cases of TB by the end of 2019. The new initiative is critically important to stopping the spread of TB and to reaching the global goal of ending TB as an epidemic by 2030.
Hilleman Laboratories   [to 14 October 2017]
Hilleman Labs achieves successful outcome of Phase I/II Clinical Trial of its Oral Cholera Vaccine Hillchol
New Delhi: Delivering on its mission to develop affordable vaccines for global health, Hilleman Laboratories today announced that it has successfully completed the Phase I/II Clinical Trials of its novel Oral Cholera Vaccine HillcholTM to address growing need to stop Cholera in the developing world.
The Phase I/II clinical study was conducted in partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b). Results of the clinical trials were announced at the Vaccines for Enteric Diseases Conference 2017 recently held in Albufeira, Portugal…

Hilleman Labs successfully completes Phase I/II Clinical Trial of its Heat Stable Rotavirus Vaccine (HSRV)
12th October 2017, New Delhi: Making headway towards providing the developing nations an affordable and easy-to-use Heat Stable Rotavirus Vaccine (HSRV), Hilleman Laboratories, a joint-venture between Merck Sharp & Dohme (MSD) and the Wellcome Trust, today announced the successful completion of Phase I/II clinical trial of its oral vaccine against the deadly Rotavirus disease.
The study was conducted in partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)…
IAVI  [to 14 October 2017]
October 2017
IAVI REPORT – VOL. 21, NO. 3, 2017
:: Decisive Moments in Wake of Paris
:: Stumbling on Greatness
:: PrEParing to Prevent HIV
:: In Brief
MSF/Médecins Sans Frontières  [to 14 October 2017]
Press release
Governments Must Step Up the Use of Newer Drugs to Fight Multidrug-Resistant TB
Guadalajara, Mexico, October 13, 2017—People with drug-resistant tuberculosis (DR-TB) are still not receiving two newer tuberculosis (TB) drugs, bedaquiline and delamanid, which have shown improved cure rates for the disease, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is meeting.
NIH  [to 14 October 2017]
October 12, 2017
NIH partners with 11 leading biopharmaceutical companies to accelerate the development of new cancer immunotherapy strategies for more patients
October 12, 2017 — Supports Cancer Moonshot goal to bring immunotherapy success to more patients in half the time.

Experimental Ebola vaccines elicit year-long immune response
October 11, 2017 — NIH reports final data from large clinical trial in West Africa.
[See Milestones/Perspectives above for more detail]

NIH completes atlas of human DNA differences that influence gene expression
October 11, 2017 — This atlas will be a critical resource for the scientific community.

Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine
October 10, 2017 — From a practical standpoint, ending the HIV/AIDS pandemic without a vaccine is unlikely.
   AS Fauci. An HIV vaccine is essential for ending the HIV/AIDS pandemic. Journal of the American Medical Association DOI: 10.1001/jama.2017.13505 (2017) (link is external).
[See Milestones/Perspectives above for more detail]

UNAIDS [to 14 October 2017]
International Day of the Girl Child: empowering girls before, during and after crises
11 October 2017
The International Day of the Girl Child, marked every year on 11 October, highlights and addresses the needs and challenges that girls face, while promoting their empowerment and human rights.
In many parts of the world, one of the key challenges that adolescent girls face is HIV. Globally, every week 6900 adolescent girls and young women aged 15–24 years are newly infected with HIV, yet only one in three adolescent girls and young women have comprehensive and correct knowledge of how to prevent HIV. In sub-Saharan Africa, three in four new HIV infections among 15–19-year-olds are among girls.
The theme of the International Day of the Girl Child 2017 is “EmPOWER girls: before, during and after crises”. War and conflict exacerbate the vulnerability of girls to child marriage, intensify inequality and make women and girls susceptible to both household and intimate partner violence, all of which increase the vulnerability of women and girls to HIV…

Press statement
UNAIDS and UNFPA launch road map to stop new HIV infections
Global HIV Prevention Coalition holds first meeting in Geneva, Switzerland, to find ways to strengthen and sustain political commitment for HIV prevention
GENEVA, 10 October 2017—As part of global efforts to end AIDS as a public health threat, UNAIDS, the United Nations Population Fund (UNFPA) and partners have launched a new road map to reduce new HIV infections. The HIV prevention 2020 road map was launched at the first meeting of the Global HIV Prevention Coalition. The coalition is chaired by the Executive Directors of UNAIDS and UNFPA and brings together United Nations Member States, civil society, international organizations and other partners as part of efforts to reduce new HIV infections by 75% by 2020…

New fund for key populations in eastern Europe and central Asia
10 October 2017
The Elton John AIDS Foundation announced on 10 October a new funding initiative for key populations in eastern Europe and central Asia.
The Key Populations Fund for Eastern Europe and Central Asia will focus on prevention and treatment of both HIV and hepatitis C for the people in the region most vulnerable to HIV—people who inject drugs, gay men and other men who have sex with men and sex workers. Over the next three years, the fund will aim to reach 20 000 people in the region with prevention, testing and treatment services…

UNICEF  [to 14 October 2017]
12 October, 2017
Violence in al-Mayadin district, Deir ez-Zor, reportedly destroys cold room and vaccines
AMMAN/DAMASCUS,– “UNICEF has received reports that ongoing violence in Deir ez-Zor in eastern Syria has destroyed a UNICEF-supported vaccine cold room in al-Mayadin district, with at least 140,000 doses of vaccines lost, including some planned for use in tackling vaccine-preventable childhood diseases in the area. UNICEF is currently verifying this alarming report.

UNICEF emergency supplies for Rohingya children en route to Cox’s Bazar
COX’S BAZAR, 14 September 2017 – UNICEF trucks filled with emergency water, sanitation and hygiene supplies for thousands of Rohingya children are headed to Cox’s Bazar, with a steady stream of supplies in the pipeline for the coming days and weeks.

World’s second largest oral cholera vaccination campaign kicks off at Rohingya camps in Bangladesh
COX’S BAZAR, Bangladesh, 10 October 2017 – A massive cholera immunization campaign started today near Cox’s Bazar, Bangladesh, to protect newly arrived Rohingya and host communities from the life-threatening diarrheal disease. 900,000 doses of the vaccine have been mobilized and are being delivered by more than 200 mobile vaccination teams, making it the second largest oral cholera vaccination campaign ever.
Wellcome Trust  [to 14 October 2017]
News / Published: 13 October 2017
Global pledges to speed up action on superbugs
Wellcome is investing £2.4 million in a new project to track the global impact of superbugs as part of our ongoing efforts to help address this urgent global health threat.
The Global Burden of Disease AMR project will be launched today at our international Call to Action conference.

News / Published: 10 October 2017
Findings from new malaria database are ‘wake-up call’
Researchers have compiled and analysed 115 years of malaria data in Africa, providing the most detailed picture yet of where efforts to control malaria infection are being won and lost across the continent.
The largest data repository of any parasitic disease in the world, it includes 7.8 million blood samples from more than 30,000 locations in 43 countries.
The open access dataset (opens in a new tab) was collected and analysed by KEMRI-Wellcome Trust (opens in a new tab) researchers Professor Bob Snow, Abdisalan Noor and colleagues based in Kenya, and is the result of over 20 years of research funded by Wellcome.

PhRMA    [to 14 October 2017]
October 12, 2017
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
A new public-private partnership will help build upon a new era in cancer treatment.

October 11, 2017
Amgen Chairman and CEO Robert A. Bradway Elected PhRMA Board Chairman-Elect
The Pharmaceutical Research and Manufacturers of America elected new officers to its board of directors.